KR20200138290A - C3-결합제 및 이의 사용 방법 - Google Patents

C3-결합제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20200138290A
KR20200138290A KR1020207030405A KR20207030405A KR20200138290A KR 20200138290 A KR20200138290 A KR 20200138290A KR 1020207030405 A KR1020207030405 A KR 1020207030405A KR 20207030405 A KR20207030405 A KR 20207030405A KR 20200138290 A KR20200138290 A KR 20200138290A
Authority
KR
South Korea
Prior art keywords
seq
heavy chain
light chain
variable region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207030405A
Other languages
English (en)
Korean (ko)
Inventor
다나 옌 메이 듀이
종하오 리우
지에 탕
얀 왕
이유안 인
웬우 자이
자레드 마틴 힉비
Original Assignee
엔지엠 바이오파마슈티컬스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔지엠 바이오파마슈티컬스, 아이엔씨. filed Critical 엔지엠 바이오파마슈티컬스, 아이엔씨.
Publication of KR20200138290A publication Critical patent/KR20200138290A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207030405A 2018-04-03 2019-04-01 C3-결합제 및 이의 사용 방법 Pending KR20200138290A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652253P 2018-04-03 2018-04-03
US62/652,253 2018-04-03
PCT/US2019/025123 WO2019195136A1 (en) 2018-04-03 2019-04-01 C3-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20200138290A true KR20200138290A (ko) 2020-12-09

Family

ID=66630340

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030405A Pending KR20200138290A (ko) 2018-04-03 2019-04-01 C3-결합제 및 이의 사용 방법

Country Status (18)

Country Link
US (3) US11136381B2 (enExample)
EP (1) EP3790897A1 (enExample)
JP (2) JP7477457B2 (enExample)
KR (1) KR20200138290A (enExample)
CN (1) CN112105638A (enExample)
AR (1) AR117565A1 (enExample)
AU (1) AU2019248557A1 (enExample)
BR (1) BR112020019907A2 (enExample)
CA (1) CA3093356A1 (enExample)
CL (2) CL2020002522A1 (enExample)
CO (1) CO2020013468A2 (enExample)
IL (1) IL277404A (enExample)
MX (1) MX2020010323A (enExample)
PE (1) PE20212132A1 (enExample)
PH (1) PH12020500664A1 (enExample)
SG (1) SG11202008897SA (enExample)
TW (1) TWI833742B (enExample)
WO (1) WO2019195136A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
WO2021226442A2 (en) 2020-05-08 2021-11-11 Ngm Biopharmaceuticals, Inc. Therapeutic uses of c3-binding agents
EP4213808A4 (en) * 2020-09-21 2024-05-22 Apellis Pharmaceuticals, Inc. Methods of treating eye disorders
WO2022171771A1 (en) * 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
CR20240265A (es) 2021-12-22 2024-10-16 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
WO2024086555A1 (en) * 2022-10-17 2024-04-25 Ngm Biopharmaceuticals, Inc. Uses of anti-c3 antibodies
CN117447601B (zh) * 2023-12-22 2024-03-08 北京索莱宝科技有限公司 猪IgM的抗体、抗体组合物及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01002580A (es) * 1998-09-10 2002-04-08 Univ Virginia Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas.
WO2004031240A1 (en) * 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US20090004183A1 (en) 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
CA2593846A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
RU2473563C2 (ru) 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
US20130177567A1 (en) 2010-05-18 2013-07-11 Sydansk Universitet Novel c3c epitope, antibodies binding thereto, and use thereof
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
CA2869477C (en) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
AU2014370404A1 (en) 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
CN116059378A (zh) * 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
WO2017048466A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Compositions and methods for delivering biotherapeutics
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法

Also Published As

Publication number Publication date
US11767359B2 (en) 2023-09-26
US20190322730A1 (en) 2019-10-24
TW202003559A (zh) 2020-01-16
CL2020002522A1 (es) 2021-02-26
RU2020135712A (ru) 2022-05-04
JP7477457B2 (ja) 2024-05-01
US11136381B2 (en) 2021-10-05
US20230382985A1 (en) 2023-11-30
PH12020500664A1 (en) 2021-06-07
MX2020010323A (es) 2021-01-08
BR112020019907A2 (pt) 2021-01-05
JP2021520195A (ja) 2021-08-19
EP3790897A1 (en) 2021-03-17
AR117565A1 (es) 2021-08-18
SG11202008897SA (en) 2020-10-29
CO2020013468A2 (es) 2020-11-10
JP2024056851A (ja) 2024-04-23
IL277404A (en) 2020-11-30
CN112105638A (zh) 2020-12-18
US20220119508A1 (en) 2022-04-21
TWI833742B (zh) 2024-03-01
AU2019248557A1 (en) 2020-09-24
PE20212132A1 (es) 2021-11-05
CA3093356A1 (en) 2019-10-10
WO2019195136A1 (en) 2019-10-10
CL2021002039A1 (es) 2022-04-01

Similar Documents

Publication Publication Date Title
US11767359B2 (en) C3-binding agents and methods of use thereof
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
US20210032347A1 (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN110475570B (zh) 抗人膜联蛋白a1抗体
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
KR20250057830A (ko) 항-인간 보체 c5 항체 및 이의 융합 단백질
US20220251241A1 (en) Htra1-binding agents and methods of use thereof
WO2021226442A2 (en) Therapeutic uses of c3-binding agents
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
EP4541820A1 (en) Monoclonal antibody against tfpi and use thereof
TW202528352A (zh) Ｋｌｒｂ１結合劑及其使用方法
JP2017528523A (ja) 線維性疾患の治療
HK1234078B (zh) 新的抗人tie-2抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
D18-X000 Deferred examination requested

St.27 status event code: A-1-2-D10-D18-exm-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D18-X000 Deferred examination requested

St.27 status event code: A-1-2-D10-D18-exm-X000

D19-X000 Deferred examination accepted

St.27 status event code: A-1-2-D10-D19-exm-X000

D20-X000 Deferred examination resumed

St.27 status event code: A-1-2-D10-D20-exm-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701